BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jang JY, Chung RT. Chronic hepatitis C. Gut Liver. 2011;5:117-132. [PMID: 21814590 DOI: 10.5009/gnl.2011.5.2.117] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Ladino M, Pedraza F, Roth D. Hepatitis C Virus Infection in Chronic Kidney Disease. J Am Soc Nephrol. 2016;27:2238-2246. [PMID: 27095799 DOI: 10.1681/asn.2016010030] [Cited by in Crossref: 55] [Cited by in F6Publishing: 19] [Article Influence: 9.2] [Reference Citation Analysis]
2 Lima LR, Moraes ML, Nigoghossian K, Peres MF, Ribeiro SJ. Silk fibroin-antigenic peptides-YVO 4 :Eu 3+ nanostructured thin films as sensors for hepatitis C. Journal of Luminescence 2016;170:375-9. [DOI: 10.1016/j.jlumin.2015.08.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 de Mesquita FC, Bitencourt S, Caberlon E, da Silva GV, Basso BS, Schmid J, Ferreira GA, de Oliveira FDS, de Oliveira JR. Fructose-1,6-bisphosphate induces phenotypic reversion of activated hepatic stellate cell. European Journal of Pharmacology 2013;720:320-5. [DOI: 10.1016/j.ejphar.2013.09.067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
4 Helal TEA, Radwan NA, Mahmoud HA, Zaki AM, Ahmed NS, Wahib AA, Aref AM. The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4. Afr Health Sci 2019;19:1411-21. [PMID: 31148968 DOI: 10.4314/ahs.v19i1.14] [Reference Citation Analysis]
5 Mozer-Lisewska I, Zwolińska K, Kowala-Piaskowska AE, Bura M, Rozpłochowski B, Pauli A, Żeromski J, Piasecki E, Kuśnierczyk P. Genetic (KIR, HLA-C) and Some Clinical Parameters Influencing the Level of Liver Enzymes and Early Virologic Response in Patients with Chronic Hepatitis C. Arch Immunol Ther Exp (Warsz) 2016;64:65-73. [PMID: 26206121 DOI: 10.1007/s00005-015-0350-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Kim TY. The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection. Korean J Hepatol 2012;18:29-31. [PMID: 22511900 DOI: 10.3350/kjhep.2012.18.1.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Safi SZ, Waheed Y, Sadat J, Solat-Ul-Islam, Salahuddin S, Saeed U, Ashraf M. Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. Asian Pac J Trop Biomed 2012;2:532-6. [PMID: 23569965 DOI: 10.1016/S2221-1691(12)60091-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
8 Dogan UB, Akin MS, Yalaki S. Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment. World J Gastroenterol 2013; 19(46): 8678-8686 [PMID: 24379586 DOI: 10.3748/wjg.v19.i46.8678] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Llanes MS, Palacios NS, Piccione M, Ruiz MG, Layana C. [Molecular aspects of the antiviral response against hepatitis C virus implicated in vaccines development]. Enferm Infecc Microbiol Clin 2015;33:273-80. [PMID: 24529681 DOI: 10.1016/j.eimc.2013.12.012] [Reference Citation Analysis]
10 Ladino M, Pedraza F, Roth D. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. World J Hepatol 2017; 9(19): 833-839 [PMID: 28740594 DOI: 10.4254/wjh.v9.i19.833] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
11 Zafar A, Imran M, Zahoor S, Shah ZH, Ali M, Afzal MS. Prevalence and Treatment of Untypable HCV Variants in Different Districts of Punjab, Pakistan. Viral Immunol 2018;31:426-32. [PMID: 29920175 DOI: 10.1089/vim.2017.0167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Sinn DH, Gwak GY, Shin JU, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels. World J Gastroenterol 2013; 19(14): 2256-2261 [PMID: 23599653 DOI: 10.3748/wjg.v19.i14.2256] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Niu Z, Zhang P, Tong Y. Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China. Springerplus 2016;5:1557. [PMID: 27652130 DOI: 10.1186/s40064-016-3224-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
14 Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RDG. Lipids and HCV. Semin Immunopathol 2013;35:87-100. [DOI: 10.1007/s00281-012-0356-2] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 7.0] [Reference Citation Analysis]
15 Dogan UB, Akin MS, Yalaki S. A low serum γ-glutamyltransferase level predicts a sustained virological response in patients with chronic hepatitis C genotype 1. Gut Liver. 2014;8:113-115. [PMID: 24516710 DOI: 10.5009/gnl.2014.8.1.113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
16 Dibrov SM, Ding K, Brunn ND, Parker MA, Bergdahl BM, Wyles DL, Hermann T. Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitches. Proc Natl Acad Sci U S A 2012;109:5223-8. [PMID: 22431596 DOI: 10.1073/pnas.1118699109] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 6.5] [Reference Citation Analysis]
17 Oguz A, Atay AE, Tas A, Seven G, Koruk M. Predictive role of acute phase reactants in the response to therapy in patients with chronic hepatitis C virus infection. Gut Liver 2013;7:82-8. [PMID: 23424009 DOI: 10.5009/gnl.2013.7.1.82] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
18 Caragea DC, Mihailovici AR, Streba CT, Schenker M, Ungureanu B, Caragea IN, Popa R, Obleaga C, Vere CC. Hepatitis C Infection in Hemodialysis Patients. Curr Health Sci J 2018;44:107-12. [PMID: 30746156 DOI: 10.12865/CHSJ.44.02.02] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 du Preez I, Sithebe NP. The use of metabolomics as a tool to investigate hepatitis C. Metabolomics 2013;9:497-505. [DOI: 10.1007/s11306-012-0467-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
20 Janda M, Mergenhagen KA. The Effect of Psychosocial Factors on Success Rates of Hepatitis C Treatment. Psychosomatics 2017;58:624-32. [PMID: 28870488 DOI: 10.1016/j.psym.2017.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
21 Martínez-Donato G, Piniella B, Aguilar D, Olivera S, Pérez A, Castañedo Y, Alvarez-Lajonchere L, Dueñas-Carrera S, Lee JW, Burr N, Gonzalez-Miro M, Rehm BH. Protective T Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System. Clin Vaccine Immunol 2016;23:370-8. [PMID: 26888185 DOI: 10.1128/CVI.00687-15] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]